A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. - Wikidata - awgldk - TriplyDB

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.

http://www.wikidata.org/entity/Q34132643

about

Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model Nonsurgical treatment of recurrent glioblastoma Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges Adaptation to antiangiogenic therapy in neurological tumors Tissue concentration of systemically administered antineoplastic agents in human brain tumors.Experimental approaches for the treatment of malignant gliomas.Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.Glial progenitors as targets for transformation in glioma.Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity.Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy.Microenvironmental stiffness enhances glioma cell proliferation by stimulating epidermal growth factor receptor signaling.Drosophila melanogaster as a model system for human brain cancers.Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.Compound 331 selectively induces glioma cell death by upregulating miR-494 and downregulating CDC20.Supramolecular Probes for Assessing Glutamine Uptake Enable Semi-Quantitative Metabolic Models in Single Cells.Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.Rapid detection of high-level oncogene amplifications in ultrasonic surgical aspirations of brain tumors.Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma.A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases.NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies.Anti-cancer Therapies in High Grade Gliomas.Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.Standards of care and novel approaches in the management of glioblastoma multiforme.Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

P2860

Q21133610-9C466EA3-E150-4FBE-AB81-732D6C193C9F Q26795560-A1D50744-87BB-4758-BA2A-095FEA422A4E Q26822717-B826407E-74B7-4780-87C6-3A6E82ABD8CF Q26829873-0D95B141-4AFC-4841-B764-1FF80B69E0B1 Q26862516-F911F1FA-DEDC-4655-B0B8-FB5985535EBE Q28082908-DB8C006E-83D1-4E64-96C9-8098C13BEE6A Q33844823-27F333C2-7F28-4C07-B0B6-C08EE77179BF Q34127138-6A2AD4BD-8722-47A3-B169-CFBE196FCCB7 Q34480689-9F4EA4B8-CD96-4783-AF9C-06D15D174E0A Q34722457-4FB97266-403A-475C-A36F-7DD641713194 Q34735661-44DFDA58-688D-44F3-83AE-CA2D1867E9DC Q34778047-718DE44F-F71A-4235-9942-C9AE5AB4347A Q34848038-9F71EB15-D1DE-45EB-AA8A-D2897DDC840A Q35027024-6ED28BE1-2AA9-4AB8-BA00-34F86C5612F8 Q35190966-CCADB0CD-E516-482B-97F6-31E25C28CCCC Q35201465-38F9C62B-80E5-4165-8F68-9E946A803033 Q35202307-073D8CD8-AD39-400E-8E02-15A2502AAE4D Q35566228-8F4904D0-0F0F-44F7-B130-A9E054146F1E Q35779256-A5369552-6B3D-4ECF-9BC4-258AAD6A8732 Q35788884-F4FDB38F-C778-44F7-912A-AD9F3D7EB147 Q35830062-C58068D9-6155-4DAC-8E3A-374BBB883E84 Q35936244-784C7523-CF51-483C-BB61-B882BE00B626 Q36062158-AE28CBFE-8AE6-40D8-AAA3-2D6B54D4F34C Q36234132-73938500-1D64-4FD2-BC54-A838EAB03B45 Q36297064-ACC6A536-3A72-4F04-8B49-DC0F95796706 Q36329368-86DFBE49-C593-4AF3-B603-6B27531C2FCA Q36497633-D63297E2-E9A9-4416-96C4-33F2E6142D27 Q36606040-F6EB3FC0-7D1F-4A38-BAF4-EEA47FAE5314 Q36613936-448FCE50-2918-45C3-BD56-3E358A0BAE67 Q36682422-AD9FFAB3-2A3B-4BEF-9823-59A4F93E9452 Q36713494-5199DE3F-8E08-458B-822A-118D9B265A20 Q36782767-01F4BB93-D4ED-4F6D-928B-A3DB72A805F5 Q36913828-B883EC9B-9A01-48C9-995F-4F34C690D236 Q36949546-9D1A77BC-F3FF-4016-862D-80CE38784FF3 Q37225334-C23A3721-2606-48B5-B101-5C7824F16979 Q37290626-09B4509A-2B73-4CFE-9001-21A7D45FF4F7 Q37308322-594A0E8F-6A0E-408D-A538-5ADCAF0C162B Q37471694-D3FE22D0-8605-4630-94F0-91B3EAAD6BE6 Q37525881-C4AE4319-ED99-4CC1-909B-19EAD11B5D8A Q37641248-18E3D817-F20D-4AF4-BEE8-34A7CB5408DE

P2860

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.

http://www.wikidata.org/entity/Q34132643

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A phase II trial of erlotinib ...... tiforme postradiation therapy.

@ast

A phase II trial of erlotinib ...... tiforme postradiation therapy.

@en

A phase II trial of erlotinib ...... tiforme postradiation therapy.

@nl

type

label

A phase II trial of erlotinib ...... tiforme postradiation therapy.

@ast

A phase II trial of erlotinib ...... tiforme postradiation therapy.

@en

A phase II trial of erlotinib ...... tiforme postradiation therapy.

@nl

prefLabel

A phase II trial of erlotinib ...... tiforme postradiation therapy.

@ast

A phase II trial of erlotinib ...... tiforme postradiation therapy.

@en

A phase II trial of erlotinib ...... tiforme postradiation therapy.

@nl

P1433

Q34132643-1EB7B2B6-9896-4B76-812E-A76AED73B411

P1476

Q34132643-E980363F-EDD9-4897-948C-AC60ABEEC38E

P2093

Q34132643-01C4F389-49D7-412E-A7AE-CAEB006230D9

Q34132643-0FE058CD-6546-4F01-973A-C718026D2403

Q34132643-20D3D558-9E9E-42E2-9170-1F2E13E8A333

Q34132643-3906849E-B750-4C07-8207-263CE761FC89

Q34132643-5D1E81FF-E140-4B5C-A6BA-081175B49C02

Q34132643-5D31C041-7B93-4AAE-9F18-63B968ADE392

Q34132643-5E28A334-E290-4131-9D02-0D554A16AF1F

Q34132643-65A3CD7A-1489-4538-80A7-3333567C4F71

Q34132643-6A69CE4D-E358-4484-9580-00C6B75CF399

Q34132643-77BB2F4B-DF7D-4A6A-8472-02ECFDA12898

P2860

Q34132643-10F636E9-E684-4EC0-91F1-15ED053F2321

Q34132643-151F6C36-144A-4822-88E7-4571F10ABC9F

Q34132643-1EB030F6-E19B-487C-AA7F-CCE3199EE2FE

Q34132643-256E18F9-278E-4519-8325-401EDCF47055

Q34132643-29DE9A24-A997-4545-8181-A5AFC4677399

Q34132643-2F1C0C6F-5A71-483E-983B-4E3DC0CCF699

Q34132643-540E84B7-9CEF-416A-8159-A3FC8A1057F6

Q34132643-57A4A084-0936-4AF4-B88C-71C9C7B1A963

Q34132643-58A2F205-A30F-4560-B0BD-B17982A6224F

Q34132643-5ADC27AA-1F53-45E6-8179-CD25E6131CF2

P304

Q34132643-AAB605A7-F464-4BCF-A949-71B555D3CD79

P31

Q34132643-99C6EC58-8685-4BF5-AE7A-F8AD2079CAA3

P356

Q34132643-DFB22DC4-FFFA-4327-A714-A4036AF4C87C

P433

Q34132643-DE2C3642-CE78-4B1F-A09A-88A22120BE26

P478

Q34132643-F39FD3FB-D873-4B2E-9508-941F8F3F938D

P577

Q34132643-079BED7B-F93C-4779-AE88-3E5069F90DD5

P5875

Q34132643-14AD2DC1-6F23-4297-BF56-7D458258130A

P698

Q34132643-7054831A-11BF-41BA-8613-3BD9021D381B

P921

Q34132643-54CA051F-D8ED-4446-B852-96675CDDE872

Q34132643-A63C07AB-A31C-4906-B799-2D86238C7D72

P932

Q34132643-E9F55220-75C3-4BD6-8467-037E418C6351

P356

P1433

P1476

A phase II trial of erlotinib ...... tiforme postradiation therapy.

@en

P2093

Andrew B Lassman

http://www.w3.org/2001/XMLSchema#string

Frank Lieberman

http://www.w3.org/2001/XMLSchema#string

H Ian Robins

http://www.w3.org/2001/XMLSchema#string

Howard A Fine

http://www.w3.org/2001/XMLSchema#string

Janet Dancey

http://www.w3.org/2001/XMLSchema#string

Jeffrey J Raizer

http://www.w3.org/2001/XMLSchema#string

John G Kuhn

http://www.w3.org/2001/XMLSchema#string

Kathleen R Lamborn

http://www.w3.org/2001/XMLSchema#string

Kenneth A Aldape

http://www.w3.org/2001/XMLSchema#string

Lauren E Abrey

http://www.w3.org/2001/XMLSchema#string

P2860

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

Molecular pathogenesis of malignant gliomas.

Update on epidermal growth factor receptor mutations in non-small cell lung cancer.

P304

95-103

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOP015

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41424782

http://www.w3.org/2001/XMLSchema#string

P698

20150372

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2940554

http://www.w3.org/2001/XMLSchema#string